Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
FATE THERAPEUTICS INC (FATE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Stern Investor Relations, Inc."
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/07/2023 8-K Other Events  Interactive Data
04/19/2023 8-K Quarterly results
02/28/2023 8-K Quarterly results
01/05/2023 8-K Termination of a Material Definitive Agreement, Cost Associated with Exit or Disposal Activities, Departure of Directors or C...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives"
11/07/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "ONO PHARMACEUTICAL CO., LTD. 8-2, Kyutaromachi 1-Chome, Chuo-ku, Osaka-shi 541-8564, JAPAN TEL : 81-6-6263-5670 FAX : 81-6-6263-2976 November 7, 2022 Fate Therapeutics, Inc. Corporate Headquarters 12278 Scripps Summit Drive San Diego, CA 92131 United States of America Attention: Mr. Scott Wolchko Re: Amendment to Collaboration and Option Agreement with respect to Collaboration Candidate 2 Dear Mr. Scott Wolchko: Reference is made to Collaboration and Option Agreement dated September 14, 2018 entered into by FATE Therapeutics, Inc. and Ono Pharmaceutical Co., Ltd. , as amended to date. Unless otherwise expressly defined in this letter agreement , the defined terms used or referenced herein have the meaning ascribed to such terms in the Agreement. The Amendment shall be effective on November...",
"Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors Multiplexed-engineered, iPSC-derived CAR T-cell Product Candidate Demonstrated Broad, Potent and Specific CAR Activity Across Multiple Preclinical Solid Tumor Models Fate and ONO to Jointly Develop and Commercialize FT825/ONO-8250 in U.S. and Europe with ONO having Exclusive Rights in Rest of World San Diego, CA – November 7, 2022 – Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that ONO Pharmaceutical Co., Ltd. has exercised its option to FT825/ONO-8250, a multiplexed-engineered, iPSC-derived, chimeric antigen receptor T-cell pro..."
11/03/2022 8-K Quarterly results
08/03/2022 8-K Quarterly results
Docs: "Stern Investor Relations, Inc."
06/30/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
12/14/2021 8-K Quarterly results
11/04/2021 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Open Market Sale AgreementSM by and between Fate Therapeutics, Inc. and Jefferies LLC"
11/04/2021 8-K Quarterly results
Docs: "Stern Investor Relations, Inc."
08/04/2021 8-K Quarterly results
08/04/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Fate Therapeutics Appoints Yuan Xu to its Board of Directors San Diego, CA - August 4, 2021 - Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appointment of Yuan Xu, Ph.D., to its Board of Directors as an independent director. Dr. Xu brings to Fate Therapeutics over 25 years of discovery, development, manufacturing, and commercial experience in the global biopharmaceuticals business, most recently serving as the Chief Executive Officer and Board Member of Legend Biotech Corporation where she led the company's efforts in advancing ciltacabtagene autoleucel from proof-of-concept in 2018 to BLA preparation in 2020. “Yuan is an accomplished leader and innovator with extensiv..."
06/07/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
01/08/2021 8-K Quarterly results
12/22/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amendment No. 2 to Amended and Restated Bylaws"
12/07/2020 8-K Other Events  Interactive Data
11/05/2020 8-K Quarterly results
Docs: "First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab. The Company is conducting a multi-center Phase 1 clinical trial of FT596, its universal, off-the-shelf, chimeric antigen receptor natural killer cell product candidate, as a monotherapy and in combination with CD20-targeted monoclonal antibody therapy for the treatment of relapsed / refractory B-cell lymphoma . The first patients have been treated at the first dose level in combination with rituximab, which enables dual-antigen targeting of both CD19 and CD20 antigens expressed on malignant B cells. In addition, the Company has initiated enrollment at the second dose level as monotherapy. FT596 is derived from a clonal master induced pluripotent stem cell line engineered with three anti-tumor..."
08/19/2020 8-K Quarterly results
08/05/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
05/05/2020 8-K Quarterly results
04/28/2020 8-K Other Events
04/02/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ...
Docs: "Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies ꟷ Collaboration leverages Company’s iPSC product platform and Janssen’s proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell product candidates &#42999",
"Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update"
03/02/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy